RTS,S malaria vaccine efficacy and immunogenicity during Plasmodium falciparum challenge is associated with HLA genotype by Nielsen, C, Vekemans, J, Lievens, M, Kester, K, Regules, J, Ockenhouse, C

WHO preferred product characteristics for new vaccines against tuberculosis by Schrager, L, Chandrasekaran, P, Fritzell, B, Hatherill, M, Lambert, P, McShane, H, Tornieporth, N, Vekemans, J

A statistical interaction between circumsporozoite protein-specific T cell and antibody responses and risk of clinical malaria episodes following vaccination with RTS,S/AS01E by Ndungu, F, Mwacharo, J, Kimani, D, Kai, O, Moris, P, Jongert, E, Vekemans, J, Olotu, A, Bejon, P

HLA-B*35-restricted CD8 T cell epitopes in the antigen 85 complex of Mycobacterium tuberculosis. by Klein, MR, Smith, S, Hammond, A, Ogg, G, King, A, Vekemans, J, Jaye, A, Lukey, P, McAdam, K

Avidity of anti-circumsporozoite antibodies following vaccination with RTS,S/AS01E in young children by Olotu, A, Clement, F, Jongert, E, Vekemans, J, Njuguna, P, Ndungu, F, Marsh, K, Leroux-Roels, G, Bejon, P

The role of immune correlates of protection on the pathway to licensure, policy decision and use of group B Streptococcus vaccines for maternal immunization: considerations from Wo... by Vekemans, J, Crofts, J, Baker, CJ, Goldblatt, D, Heath, PT, Madhi, SA, Le Doare, K, Andrews, N, Pollard, AJ, Saha, SK, Schrag, SJ, Smith, PG, Kaslow, DC

Serological evidence of discrete spatial clusters of Plasmodium falciparum parasites. by Bejon, P, Turner, L, Lavstsen, T, Cham, G, Olotu, A, Drakeley, C, Lievens, M, Vekemans, J, Savarese, B, Lusingu, J, von Seidlein, L, Bull, P, Marsh, K, Theander, T

Circumsporozoite-specific T cell responses in children vaccinated with RTS,S/AS01E and protection against P falciparum clinical malaria. by Olotu, A, Moris, P, Mwacharo, J, Vekemans, J, Kimani, D, Janssens, M, Kai, O, Jongert, E, Lievens, M, Leach, A, Villafana, T, Savarese, B, Marsh, K, Cohen, J, Bejon, P

Antigen-specific IL-2 secretion correlates with NK cell responses after immunization of Tanzanian children with the RTS,S/AS01 malaria vaccine. by Horowitz, A, Hafalla, J, King, E, Lusingu, J, Dekker, D, Leach, A, Moris, P, Cohen, J, Vekemans, J, Villafana, T, Corran, P, Bejon, P, Drakeley, C, von Seidlein, L, Riley, E

Assessment of severe malaria in a multicenter, phase III, RTS, S/AS01 malaria candidate vaccine trial: case definition, standardization of data collection and patient care. by Vekemans, J, Marsh, K, Greenwood, B, Leach, A, Kabore, W, Soulanoudjingar, S, Asante, K, Ansong, D, Evans, J, Sacarlal, J, Bejon, P, Kamthunzi, P, Salim, N, Njuguna, P, Hamel, M, Otieno, W, Gesase, S, Schellenberg, D

Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection by Feng, S, Phillips, DJ, White, T, Sayal, H, Aley, PK, Bibi, S, Dold, C, Fuskova, M, Gilbert, SC, Hirsch, I, Humphries, HE, Jepson, B, Kelly, EJ, Plested, E, Shoemaker, K, Thomas, KM, Vekemans, J, Villafana, TL, Lambe, T, Pollard, AJ, Voysey, M

Immunogenicity and safety of AZD2816, a beta (B.1.351) variant COVID-19 vaccine, and AZD1222 (ChAdOx1 nCoV-19) as third-dose boosters for previously vaccinated adults: a multicentr... by Ramasamy, MN, Kelly, EJ, Seegobin, S, Dargan, PI, Payne, R, Libri, V, Adam, M, Aley, PK, Martinez-Alier, N, Church, A, Jepson, B, Khan, M, Matthews, S, Townsend, GT, Vekemans, J, Bibi, S, Swanson, PA, Lambe, T, Pangalos, MN, Villafana, T, Pollard, AJ, Green, JA

Safety and immunogenicity of the novel plasmodium falciparum blood-stage vaccine chad63-mva rh5 in a phase ia clinical trial by Payne, R, Silk, S, Elias, S, Miura, K, Diouf, A, Alanine, D, Jin, J, Labbe, G, Brian, I, Poulton, I, Griffiths, O, Edwards, N, Berrie, E, Siani, L, Douglas, A, Roberts, R, Vekemans, J, Nugent, F, Hill, A, Long, C, Lawrie, A, Draper, S

Effect of the pre-erythrocytic candidate malaria vaccine RTS,S/AS01E on blood stage immunity in young children. by Bejon, P, Cook, J, Bergmann-Leitner, E, Olotu, A, Lusingu, J, Mwacharo, J, Vekemans, J, Njuguna, P, Leach, A, Lievens, M, Dutta, S, von Seidlein, L, Savarese, B, Villafana, T, Lemnge, M, Cohen, J, Marsh, K, Corran, P, Angov, E, Riley, E, Drakeley, C

Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age. by Bejon, P, Lusingu, J, Olotu, A, Leach, A, Lievens, M, Vekemans, J, Mshamu, S, Lang, T, Gould, J, Dubois, M, Demoitié, M, Stallaert, J, Vansadia, P, Carter, T, Njuguna, P, Awuondo, K, Malabeja, A, Abdul, O, Gesase, S, Mturi, N, Drakeley, C, Savarese, B, Villafana, T, Ballou, W, Cohen, J

Efficacy of RTS,S/AS01E malaria vaccine and exploratory analysis on anti-circumsporozoite antibody titres and protection in children aged 5-17 months in Kenya and Tanzania: a rando... by Olotu, A, Lusingu, J, Leach, A, Lievens, M, Vekemans, J, Msham, S, Lang, T, Gould, J, Dubois, M, Jongert, E, Vansadia, P, Carter, T, Njuguna, P, Awuondo, K, Malabeja, A, Abdul, O, Gesase, S, Mturi, N, Drakeley, C, Savarese, B, Villafana, T, Lapierre, D, Ballou, W, Cohen, J, Lemnge, M

Efficacy of RTS,S/AS01E malaria vaccine and exploratory analysis on anti-circumsporozoite antibody titres and protection in children aged 5-17 months in Kenya and Tanzania: a rando... by Olotu, A, Lusingu, J, Leach, A, Lievens, M, Vekemans, J, Msham, S, Lang, T, Gould, J, Dubois, M, Jongert, E, Vansadia, P, Carter, T, Njuguna, P, Awuondo, K, Malabeja, A, Abdul, O, Gesase, S, Mturi, N, Drakeley, C, Savarese, B, Villafana, T, Lapierre, D, Ballou, W, Cohen, J, Lemnge, M

PHASE IIB, RANDOMIZED, DOUBLE-BLIND TRIAL TO ASSESS THE EFFICACY, SAFETY AND IMMUNOGENICITY OF THE CANDIDATE MALARIA VACCINE RTS,S/AS01 IN KENYAN AND TANZANIAN CHILDREN by Bejon, P, Lusingu, J, Olotu, A, Leach, A, Lievens, M, Vekemans, J, Msham, S, Lang, T, Gould, J, Dubois, M, Demoitie, M, Vansadia, P, Carter, T, Njuguna, P, Kawuondo, K, Gesase, S, Drakeley, C, Savarese, B, Villafana, T, Ballou, W, Cohen, J, Riley, E, Lemnge, M, Marsh, K, von Seidlein, L

Stillbirth with group B Streptococcus disease worldwide: systematic review and meta-analyses by Seale, AC, Blencowe, H, Bianchi-Jassir, F, Embleton, N, Bassat, Q, Ordi, J, Menéndez, C, Cutland, C, Briner, C, Berkley, JA, Lawn, JE, Baker, CJ, Bartlett, L, Gravett, MG, Heath, PT, Ip, M, Le Doare, K, Rubens, CE, Saha, SK, Schrag, S, Meulen, AS-T, Vekemans, J, Madhi, SA

Safety and immunogenicity of ChAd63/MVA Pfs25-IMX313 in a Phase I first-in-human trial by de Graaf, H, Payne, RO, Taylor, I, Miura, K, Long, CA, Elias, SC, Zaric, M, Minassian, AM, Silk, SE, Li, L, Poulton, ID, Baker, M, Draper, SJ, Gbesemete, D, Brendish, NJ, Martins, F, Marini, A, Mekhaiel, D, Edwards, NJ, Roberts, R, Vekemans, J, Moyle, S, Faust, SN, Berrie, E, Lawrie, AM, Hill, F, Hill, AVS, Biswas, S